Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Papyrus Holding AB
Mandate

Vinge has advised Papyrus Holding AB

January 11, 2017

Vinge has advised Papyrus Holding AB in connection with its acquisition of Procurator AB from RoosGruppen AB. The Procurator-group is one of the leading suppliers of inter alia protective clothing and personal protective equipment and cleaning and hygiene products in Sweden, Finland, Norway, Denmark and Estonia. The company had revenues of approx. MEUR 120 in 2015. The transaction is subject to relevant approval from the Swedish Competition Authority.

Vinge´s team consisted of partners in charge Christina Kokko (M&A) and Anna Palmérus (competition law) and among others Kristina Ekberg, Oscar Rydén, Johanna Wiberg and Ilze Lukins (M&A), Frida Ställborn (competition law), Sara Strandberg and Lisa Sennerby (employment), Josefine Lanker (financing), Tomas Forsgren (IP), Nicklas Thorgerzon (IT), Kristoffer Larson (real estate), Jasmin Draszka-Ali (CSR) and Andréa Nicolin (agreements).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026